Trial Profile
An observational, prospective, non-interventional, cohort study in relapsed and refractory Chronic Lymphocytic Leukemia patients retreated with Rituximab
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2018
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms PERLE
- 01 Sep 2016 New trial record